BREAST AND OVARIAN CANCER-SPECIFIC CYTOTOXIC T-LYMPHOCYTES RECOGNIZE THE SAME HER2/NEU-DERIVED PEPTIDE
BREAST AND OVARIAN CANCER-SPECIFIC CYTOTOXIC T-LYMPHOCYTES RECOGNIZE THE SAME HER2/NEU-DERIVED PEPTIDE
复制标题
DOI：
10.1073/pnas.92.2.432
复制
发表时间：
1995-01-17
影响因子：
11.1
通讯作者：
EBERLEIN, TJ
中科院分区：
文献类型：
--
作者：
PEOPLES, GE;GOEDEGEBUURE, PS;EBERLEIN, TJ
识别肿瘤细胞表面由人类白细胞抗原I类分子呈现并被肿瘤特异性细胞毒性T淋巴细胞识别的抗原肽，可能导致一种能够诱导保护性细胞免疫的多肽疫苗。我们证明了人类白细胞抗原A2限制的乳腺和卵巢肿瘤特异性细胞毒性T淋巴细胞都识别共同的抗原肽。这些多肽中至少有一种来自HER2/neu的癌基因产物，该基因在30%-40%的乳腺癌和卵巢癌中过度表达。对此九个氨基酸序列致敏的T细胞表现出对人类白细胞抗原A2(+)、HER2/neu(+)肿瘤的显著识别能力。由于人类白细胞抗原-A2(+)占肿瘤细胞总数的50%，且多种肿瘤都表达HER2/neu，因此HER2/neu多肽具有广泛的认知性和临床应用价值。
The identification of antigenic peptides presented on the tumor cell surface by HLA class I molecules and recognized by tumor-specific cytotoxic T lymphocytes may lead to a peptide vaccine capable of inducing protective cellular immunity. We demonstrate that both HLA-A2-restricted breast and ovarian tumor-specific cytotoxic T lymphocytes recognize shared antigenic peptides. At least one of these peptides is derived from the oncogene product of HER2/neu, which is overexpressed in 30-40% of all breast and ovarian cancers. T cells sensitized against this nine-amino acid sequence demonstrate significant recognition of HLA-A2(+), HER2/neu(+) tumors. Since 50% of ther tumor-cell population is HLA-A2(+) and many different tumors express HER2/neu, this peptide may be widely recognized and have many clinical applications.